Health Canada approves Zolgensma®, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)
Novartis faces serious delays in registration of Zolgensma in Russia
Novartis's SMA gene therapy Zolgensma to be available for NHS use - Pharmaceutical Technology
News Archive | Novartis
Novartis Media Release guide - August 2019
Zolgensma launch 'on track and fully in line' with expectation, says Novartis CEO | Fierce Pharma
Novartis releases long-term data for SMA gene therapy
Path clears for Novartis's Zolgensma after FDA lifts longstanding hold
Zolgensma® Data Shows Rapid, Significant, Clinically Meaningful Benefit in SMA, Including Prolonged Event-free Survival, Motor Milestone Achievement and Durability, Now Up to 5 Years Post-dosing - Cure SMA
Novartis says it knew of Zolgensma data problems before U.S. approval - The Japan Times
Health Canada approves Zolgensma®, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)
Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonge
Zolgensma gene therapy for sma patients: long-term data
Novartis Boosts Zolgensma Production Capacity After FDA Clearance
Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event- free survival, motor
R&D report card: Zolgensma-maker Novartis' spending reaches $9.4B in 2019 | S&P Global Market Intelligence
Novartis allies with Voyager to develop gene therapies in $1.3bn deal
Zolgensma SMA therapy confirms long-term efficacy for up to 7.5 years < Pharma < Article - KBR
ICNApedia - Zolgensma Benefits Observed in Presymptomatic SMA Patients
Novartis Lauds Quebec's Move to Reimburse SMA Patients for Zolgensma
Novartis Reveals Two Deaths Related to SMA Drug Zolgensma | BioSpace
Test Achats porte plainte contre un médicament à 2 millions d'euros
EMA seeks to issue guidance on liver damage from Novartis' gene therapy | Reuters
Novartis slaps $2M-plus price tag on newly approved gene therapy Zolgensma—and cost watchdogs approve | Fierce Pharma
Novartis expands Zolgensma manufacturing capacity with approval of multi-product North Carolina facility
Novartis to Open New Trial of Zolgensma for Older SMA Patients
